Artificial intelligence for digital and computational pathology
Advances in digitizing tissue slides and the fast-paced progress in artificial intelligence,
including deep learning, have boosted the field of computational pathology. This field holds …
including deep learning, have boosted the field of computational pathology. This field holds …
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
Breast cancer is a heterogeneous disease with variable survival outcomes. Pathologists
grade the microscopic appearance of breast tissue using the Nottingham criteria, which are …
grade the microscopic appearance of breast tissue using the Nottingham criteria, which are …
Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes
Computational methods have made substantial progress in improving the accuracy and
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
Morphological and molecular breast cancer profiling through explainable machine learning
Recent advances in cancer research and diagnostics largely rely on new developments in
microscopic or molecular profiling techniques, offering high levels of detail with respect to …
microscopic or molecular profiling techniques, offering high levels of detail with respect to …
Artificial intelligence to identify genetic alterations in conventional histopathology
Precision oncology relies on the identification of targetable molecular alterations in tumor
tissues. In many tumor types, a limited set of molecular tests is currently part of standard …
tissues. In many tumor types, a limited set of molecular tests is currently part of standard …
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working …
J Thagaard, G Broeckx, DB Page… - The Journal of …, 2023 - Wiley Online Library
The clinical significance of the tumor‐immune interaction in breast cancer is now
established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and …
established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and …
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast …
PI Gonzalez‐Ericsson, ES Stovgaard… - The Journal of …, 2020 - Wiley Online Library
Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care
in oncology across several hematologic and solid tumor types, including triple negative …
in oncology across several hematologic and solid tumor types, including triple negative …